At the start of October 2016 Japanese cell biologist Yoshinori Ohsumi was awarded the Nobel Prize in Physiology or Medicine 'for his discoveries of mechanisms for autophagy', autophagy being an intracellular degradation pathway that helps maintain cytoplasmic homeostasis. This commentary discusses Ohsumi's Nobel prize-winning work in context, before explaining the clinical relevance of autophagy.
Introduction
Macroautophagy (hereafter referred to as autophagy) is an important means of maintaining cellular homeostasis by trafficking cytoplasmic material for enzymatic degradation in the lysosome. In mammalian cells, the process involves formation of a cup-shaped, doublemembraned phagophore (or isolation membrane), which closes around cytoplasmic material to form a spherical, double-membraned autophagosome ( Figure 1A ). The autophagosome outer membrane ultimately fuses with a lysosome to form an autolysosome, resulting in degradation of the inner autophagosome membrane and sequestered cargo. Autophagy is both a constitutive process and subject to dynamic regulation by a range of physiological signals.
Notably, autophagy is induced by nutrient starvation. The substrates of autophagy are extremely diverse, ranging from organelles such as mitochondria, through to aggregate-prone proteins and invading microorganisms.
Characterisation of autophagy in yeast
Yoshinori Ohsumi's first contribution to autophagy research was demonstrating that autophagy in yeast is similar to that in mammalian cells ( Figure 1B 
Regulation of mammalian autophagy
The response of autophagy to various physiological stimuli was also investigated in these early days, with de Duve and colleagues reporting that administering glucagon to rats upregulates autophagy in the liver. (6) This observation fits with autophagy induction in response to nutrient starvation as a means of producing amino acids for gluconeogenesis and other metabolic pathways; a hypothesis that was borne out almost a decade later, when amino acid depletion was shown to upregulate autophagy in both cultured human cells and rat liver. (7, 8) Analysis of the signalling events linking nutrient starvation to autophagy induction was to follow. A breakthrough came when Alfred Meijer's group, working in hepatocytes isolated from starved rats, noted that phosphorylation of ribosomal protein S6 paralleled the decrease in autophagy observed when amino acids were added to the culture medium. The immunosuppressive drug rapamycin, which indirectly inhibits S6 phosphorylation by antagonising mTOR (mammalian target of rapamycin) function, was then shown to induce autophagy. (9) This work uncovered the role of mTOR signalling in autophagy regulation and established rapamycin as the first drug in the expanding class of autophagy inducers.
Molecular mechanisms of autophagy
The morphology and regulation of autophagy were therefore beginning to be understood, yet none of the molecular machinery was known. At this point the Ohsumi and colleagues performed their first pioneering screens. The group used yeast lacking vacuolar proteases, which normally accumulate autophagic bodies under nutrient starvation, to identify fifteen autophagy-defective mutant yeast strains that failed to form autophagic bodies. In this way, they initially identified fifteen novel autophagy genes (now referred to as ATG genes). 
